Thea Van Rossum,Annette Haiß,Rebecca L Knoll,Janina Marißen,Daniel Podlesny,Julia Pagel,Marina Bleskina,Maren Vens,Ingmar Fortmann,Bastian Siller,Isabell Ricklefs,Jonas Klopp,Katja Hilbert,Claudius Meyer,Roman Thielemann,Sybelle Goedicke-Fritz,Martin Kuntz,Christian Wieg,Norbert Teig,Thorsten Körner,Angela Kribs,Hannes Hudalla,Markus Knuf,Anja Stein,Christian Gille,Soyhan Bagci,Frank Dohle,Hans Proquitté,Dirk M Olbertz,Esther Schmidt,Lutz Koch,Sabine Pirr,Jan Rupp,Juliane Spiegler,Matthias V Kopp,Wolfgang Göpel,Egbert Herting,Sofia K Forslund,Dorothee Viemann,Michael Zemlin,Peer Bork,Stephan Gehring,Inke R König,Philipp Henneke,Christoph Härtel

Abstract:Importance: The effects of probiotic interventions on colonization with resistant bacteria and early microbiome development in preterm infants remain to be clarified. Objective: To examine the efficacy of Bifidobacterium longum subsp infantis, Bifidobacterium animalis subsp lactis (BB-12), and Lactobacillus acidophilus (La-5) probiotics to prevent colonization with multidrug-resistant organisms or highly epidemic bacteria (MDRO+) and to shape the microbiome of preterm infants toward the eubiotic state of healthy full-term infants. Design, setting, and participants: The multicenter, double-blinded, placebo-controlled, group sequential, phase 3 Priming Immunity at the Beginning of Life (PRIMAL) randomized clinical trial, conducted from April 2018 to June 2020, included infants with gestational age of 28 to 32 weeks at 18 German neonatal units. Data analyses were conducted from March 2020 to August 2023. Intervention: A total of 28 days of multistrain probiotics diluted in human milk/formula starting within the first 72 hours of life. Main outcomes and measures: Colonization with MDRO+ at day 30 of life (primary end point), late-onset sepsis and severe gastrointestinal complication (safety end points), and gut dysbiosis, ie, deviations from the microbiome of healthy, term infants (eubiosis score) based on 16-subunit ribosomal RNA and metagenomic sequencing. Results: Among the 643 infants randomized until the stop of recruitment based on interim results, 618 (median [IQR] gestational age, 31.0 [29.7-32.1] weeks; 333 male [53.9%]; mean [SD] birth weight, 1502 [369] g) had follow-up at day 30. The interim analysis with all available data from 219 infants revealed MDRO+ colonization in 43 of 115 infants (37.4%) in the probiotics group and in 39 of 104 infants (37.5%) in the control group (adjusted risk ratio, 0.99; 95% CI, 0.54-1.81; P = .97). Safety outcomes were similar in both groups, ie, late-onset sepsis (probiotics group: 8 of 316 infants [2.5%]; control group: 12 of 322 infants [3.7%]) and severe gastrointestinal complications (probiotics group: 6 of 316 infants [1.9%]; control group: 7 of 322 infants [2.2%]). The probiotics group had higher eubiosis scores than the control group at the genus level (254 vs 258 infants; median scores, 0.47 vs 0.41; odds ratio [OR], 1.07; 95% CI, 1.02-1.13) and species level (96 vs 83 infants; median scores, 0.87 vs 0.59; OR, 1.28; 95% CI, 1.19-1.38). Environmental uptake of the B infantis probiotic strain in the control group was common (41 of 84 [49%]), which was highly variable across sites and particularly occurred in infants with a sibling who was treated with probiotics. Conclusions and relevance: Multistrain probiotics did not reduce the incidence of MDRO+ colonization at day 30 of life in preterm infants but modulated their microbiome toward eubiosis. Trial registration: German Clinical Trials Register: DRKS00013197.

The Role of Infant Gut Microbiota Modulation by Perinatal Maternal Probiotic Intervention in Atopic Eczema Risk Reduction

Antibiotic Exposure Prevents Acquisition of Beneficial Metabolic Functions in the Preterm Infant Gut Microbiome

Eczema-protective probiotic alters infant gut microbiome functional capacity but not composition: sub-sample analysis from a RCT

Early-life gut microbiota associates with allergic rhinitis during 13-year follow-up in a Finnish probiotic intervention cohort

Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial

Long Term Development of Gut Microbiota Composition in Atopic Children: Impact of Probiotics

Reversible aberrancies in gut microbiome of moderate and late preterm infants: results from a randomized, controlled trial

Effects of pregnancy and lactation prebiotics supplementation on infant allergic disease: a randomized controlled trial

Prevention of Atopic Dermatitis in Mice by <i>Lactobacillus Reuteri</i> Fn041 Through Induction of Regulatory T Cells and Modulation of the Gut Microbiota

Probiotics and gut health in infants: A preliminary case-control observational study about early treatment with Lactobacillus reuteri DSM 17938

Maternal prebiotic supplementation during pregnancy and lactation modifies the microbiome and short chain fatty acid profile of both mother and infant

Long-term safety and efficacy of perinatal probiotic intervention: Evidence from a follow-up study of four randomized, double-blind, placebo-controlled trials

The prevention effect of probiotics against eczema in children: an update systematic review and meta-analysis

Clinical study on prevention of atopic dermatitis by oral administration of probiotics in infants

Probiotics and Gut Dysbiosis in Preterm Infants

Maternal oral probiotic use is associated with decreased breastmilk inflammatory markers, infant fecal microbiome variation, and altered recognition memory responses in infants-a pilot observational study

Origin of the neonatal gut microbiota and probiotic intervention: a randomized controlled trial

Probiotic Bacteria in the Management of Atopic Disease: Underscoring the Importance of Viability

Protective effect of probiotics in the treatment of infantile eczema

Early gut colonization by Bifidobacterium breve and B. catenulatum differentially modulates eczema risk in children at high risk of developing allergic disease

Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants: The PRIMAL Randomized Clinical Trial